Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
Aug 03, 2026
Global Payments (GPN): Can It Reach $100 With +19% Upside?

Global Payments (GPN): Can It Reach $100 With +19% Upside?

Key Takeaways

  • Price Target: Global Payments Inc. (GPN) last closed at $84.08, and the $100 level represents a psychological round-number target that aligns with several Wall Street analyst price objectives — implying roughly 19% upside from current trading levels.
  • Bullish Catalysts: The completed $24 billion Worldpay acquisition, a $500 million accelerated share buyback program, AI-powered product launches, and improving competitive positioning in merchant acquiring all support the case for a move higher.
  • Key Risks: Integration risk from the Worldpay deal, elevated debt levels, intense fintech competition from names like FOUR and XYZ, and travel-related revenue headwinds tied to geopolitical uncertainty could delay or derail upward momentum.
  • Technical Landscape: The stock faces near-term resistance in the $90–$92 zone, with the psychologically significant $100 mark representing the next major upside hurdle. Support is established near the $62–$65 area, the stock's 52-week lows.
  • Bottom Line: Reaching $100 appears achievable if management executes on Worldpay synergies and the broader payments sector stabilizes, but the path depends heavily on sustained earnings growth and successful deleveraging.

Why the $100 Level Stands Out

Global Payments Inc. (GPN), a leading provider of payment processing and software solutions serving merchants and financial institutions across 30 countries, has seen its stock endure a turbulent period. After trading above $110 in early 2025, shares slumped roughly 30% before stabilizing. Now hovering in the low-to-mid $80s, the $100 mark has emerged as a natural focal point — it represents a round-number psychological barrier, aligns with multiple published analyst targets, and would mark a decisive break from the stock's recent downtrend. Morgan Stanley explicitly set a $100 price target when upgrading the stock to Overweight in July 2026, while Argus Research and Raymond James have also published targets at or near this level.

Catalysts That Could Support a Move Higher

The most significant catalyst is the Worldpay integration. Global Payments completed the $24 billion acquisition in January 2026, a transformative deal that expands its merchant base, payment volume, and global reach. Early checks on both the Genius point-of-sale platform and Worldpay's enterprise business have turned increasingly constructive, according to Morgan Stanley's recent upgrade note. Management has guided for adjusted earnings per share (EPS) growth in the mid-teens for fiscal 2026 and 2027, supported by cost synergies and operating leverage from the combined entity.

Beyond M&A execution, the company continues to invest in innovation. Global Payments recently launched an AI-powered handheld point-of-sale device featuring voice-ordering technology, secured a deal to supply point-of-sale solutions to over 2,400 CKE Restaurants locations (Hardee's and Carl's Jr.), and expanded its embedded payments partnership with Lightspeed DMS. These initiatives strengthen competitive positioning in high-growth verticals like restaurants and automotive commerce. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Capital returns provide another tailwind. The company has committed to $2 billion in capital returns for 2026, including an accelerated $500 million share repurchase program. Aggressive buybacks can meaningfully boost EPS and signal management confidence in the stock's undervaluation.

Potential Obstacles to Watch

The bear case centers on execution and leverage. Integrating Worldpay — an enormous transaction even by industry standards — carries meaningful operational and cultural risks. Some analysts, including those at William Blair, have expressed skepticism that traditional payment processors like Global Payments can deliver durable economic growth amid competition from next-generation, software-centric rivals such as AFRM and FOUR.

The balance sheet also warrants attention. Global Payments carries an enterprise value of approximately $40.7 billion against a market capitalization near $23 billion, reflecting substantial debt from the Worldpay deal. A debt-to-asset ratio above 40% leaves limited room for error should revenue growth disappoint or interest rates remain elevated. Travel-related revenue exposure — particularly to the Middle East region — adds geopolitical uncertainty that several analysts flagged when trimming second-half estimates.

Additionally, the analyst community remains split. While 6 analysts rate the stock a Buy, 8 maintain Hold ratings, and firms like Rothschild & Co Redburn have issued Sell ratings with targets as low as $60. This lack of consensus reflects genuine disagreement about whether the Worldpay combination will ultimately create or destroy shareholder value.

Key Technical Levels

From a technical perspective, GPN has been constructing a base after testing support near the $62–$65 zone multiple times throughout 2026. The stock's recent recovery toward the mid-$80s suggests buyers are beginning to absorb selling pressure, but overhead resistance remains formidable. The $90–$92 band — aligning with prior consolidation areas and moving-average resistance — represents the first major test. A sustained close above that zone would shift the intermediate-term trend from bearish to neutral and open a path toward $100. Failure to hold current levels, conversely, would put the 52-week lows back in focus.

Analyst Consensus and Price Targets

The consensus among 34 analysts tracked by S&P Global points to an average 12-month price target of approximately $94, with a high of $135 (Monness) and a low of $60 (Rothschild & Co Redburn). The median target sits near $88–$90. Morgan Stanley's recent upgrade to $100 was particularly notable given the firm had previously maintained a cautious Equalweight rating with a $65 target. Mizuho Securities holds an Outperform rating with a $110 target, while Citi initiated coverage with a Buy and a $110 objective. On the cautious side, UBS maintains a Neutral rating with an $87 target, and several firms have trimmed estimates citing travel headwinds and integration uncertainty. The wide dispersion — from $60 to $135 — underscores the binary nature of the Worldpay integration outcome.

Using AI Tools to Monitor Developments

When following names like GPN, I find it helpful to leverage tools that provide ongoing market insights. Tickeron’s AI Daily Buy/Sell Signals apply artificial intelligence to scan thousands of stocks and ETFs around the clock, producing Buy, Sell, or Hold signals drawn from real-time technical behavior, pattern recognition, and AI-driven analysis. These signals assist in spotting fresh opportunities, managing current positions, and detecting trend shifts without the need to review hundreds of charts manually. For investors tracking GPN’s progress toward the $100 level, they can deliver timely, data-driven updates as conditions change.

My Assessment of the Path Forward

The question of whether Global Payments can reach $100 is ultimately a question about execution. The stock's current valuation — trading at roughly 6 times forward earnings estimates and below book value — suggests the market is pricing in significant skepticism. If management delivers on Worldpay cost synergies, sustains mid-teens EPS growth, and uses its buyback authorization aggressively, the path to $100 appears realistic within a 12-to-18-month horizon. The Morgan Stanley upgrade and improving customer feedback on both the Genius and Worldpay platforms offer early validation of the bull case. However, the risks are genuine: elevated leverage, intense competitive pressure from agile fintech disruptors, and geopolitical headwinds all represent legitimate obstacles. Investors should monitor quarterly earnings reports for evidence of organic revenue growth, margin expansion, and debt reduction as the key signposts on the road to $100.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: GPN

GPN in downward trend: price dove below 50-day moving average on September 17, 2026

GPN moved below its 50-day moving average on September 17, 2026 date and that indicates a change from an upward trend to a downward trend. In 34 of 42 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GPN as a result. In 58 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 68%.

The 10-day moving average for GPN crossed bearishly below the 50-day moving average on September 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GPN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.

The Aroon Indicator for GPN entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GPN's RSI Indicator exited the oversold zone, 21 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 60%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where GPN advanced for three days, in 195 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

GPN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.970) is normal, around the industry mean (8.137). P/E Ratio (40.142) is within average values for comparable stocks, (60.108). Projected Growth (PEG Ratio) (0.207) is also within normal values, averaging (1.946). Dividend Yield (0.012) settles around the average of (0.013) among similar stocks. P/S Ratio (2.162) is also within normal values, averaging (9.694).

The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. GPN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GPN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.

Industry description

The industry produces equipment regularly used in offices by businesses and other organizations, and could range from items like Blank sheet paper, calendars, Label and adhesive paper, paper clips, janitorial supplies, to larger /higher cost products like computers, printers, photocopiers, office furniture and so on. Many businesses in the office supply industry have been expanding into related markets like business cards, plus printing and binding of high quality, high volume business and engineering documents. Some companies in this industry also offer shipping services, including packaging and bulk mailing. Herman Miller, Inc., Steelcase Inc. and HNI Corporation.

Market Cap

The average market capitalization across the Office Equipment/Supplies Industry is 7.06B. The market cap for tickers in the group ranges from 47.27K to 80.14B. CTAS holds the highest valuation in this group at 80.14B. The lowest valued company is KUBR at 47.27K.

High and low price notable news

The average weekly price growth across all stocks in the Office Equipment/Supplies Industry was -1%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -2%. DLHC experienced the highest price growth at 18%, while SMX experienced the biggest fall at -43%.

Volume

The average weekly volume growth across all stocks in the Office Equipment/Supplies Industry was 6%. For the same stocks of the Industry, the average monthly volume growth was 13% and the average quarterly volume growth was -34%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 53
Price Growth Rating: 61
SMR Rating: 73
Profit Risk Rating: 85
Seasonality Score: 28 (-100 ... +100)
View a ticker or compare two or three
GPN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of electronic transaction processing, electronic fund transfer and other merchant services

Industry OfficeEquipmentSupplies

Industry
Data Processing Services
Address
3550 Lenox Road
Phone
+1 770 829-8000
Employees
26000
Web
https://www.globalpayments.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.
Global Payments (GPN): Can It Reach $100 With +19% Upside?